Alterity Therapeutics Limited
ATHE · NASDAQ
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.08 | 0.05 | 0.02 | -0.07 |
| FCF Yield | -3.04% | -18.31% | -28.55% | -31.90% |
| EV / EBITDA | -6.26 | -5.48 | -1.09 | -0.38 |
| Quality | ||||
| ROIC | -16.89% | -77.51% | -79.90% | -14.27% |
| Gross Margin | 98.33% | 96.04% | 96.53% | 96.11% |
| Cash Conversion Ratio | – | 1.17 | 0.64 | – |
| Growth | ||||
| Revenue 3-Year CAGR | 29.65% | 17.53% | 17.03% | 0.50% |
| Free Cash Flow Growth | 71.83% | -3.07% | -66.75% | 21.61% |
| Safety | ||||
| Net Debt / EBITDA | 4.64 | 0.59 | 0.85 | 1.45 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -665.39 | -2,586.98 | -538.82 | -4,146.69 |